Frusemide causes acute increases in lipid concentrations.

In a randomized double-blind placebo controlled parallel study involving fourteen healthy male volunteers, we examined whether the acute reduction in vascular volume associated with frusemide ingestion would haemoconcentrate lipid particles. Three hours after a single 40 mg oral dose of frusemide, there were 9.6-14.4% increases in lipids and lipoproteins which were highly correlated to changes in body weight. Until further studies determine the extent of haemoconcentration in patients being treated long term with frusemide, we recommend that blood be drawn for lipid analysis prior to frusemide ingestion.

RCT Entities:   Population Interventions Outcomes